bony metastases
Recently Published Documents


TOTAL DOCUMENTS

153
(FIVE YEARS 27)

H-INDEX

23
(FIVE YEARS 2)

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 262-262
Author(s):  
Winnie Kam ◽  
Angela Mattia ◽  
Lara Scrimenti ◽  
German Rodriguez ◽  
Camilita Rahat ◽  
...  

262 Background: Patients with cancer are at particularly high risk for falls and unfortunately may suffer worse outcomes with falls. Patients with cancer are at increased risk for fractures due to bony metastases, and worse subsequent bleeding due to thrombocytopenia from disease or from prophylaxis or treatment for deep vein thromboses. In 2020, there were 10 falls among patients with cancer in NewYork Presbyterian/Weill Cornell Medicine outpatient oncology clinics, with a fall rate of 0.31 falls per 1000 patient visit. In 2019, there were 14 falls (0.39 falls per 1000 patient visits).The aim of this project is to reduce the total number of falls and overall fall rate by 50% in NewYork Presbyterian/Weill Cornell Medicine outpatient oncology clinic areas by December 30, 2021. Methods: In Plan-Do-Study-Act (PDSA) cycle in February 2021, we identified key stakeholders (nurses, medical assistants, nurse navigators, and clinic managers) in NYP/Weill Cornell oncology outpatient areas. We engaged key stakeholders in a series of interactive conferences to introduce and implement quality improvement tools (root cause analysis and process mapping) with outpatient teams to identify risk factors for patients who fell in NYP/Weill Cornell oncology outpatient areas from 01/2020-12/2021. A standardized post-fall huddle process was implemented, and prior falls were reviewed using this process. Interventions were based on these identified risk factors to prevent falls in the outpatient clinic areas. In the second PDSA cycle which began April 1, 2021, a new handoff process was initiated in the outpatient clinic setting. Prior to the end of the shift, the charge nurse cross references the “G Drive list” with patient list for the following day and identifies patients with previous falls or those identified by nurses as being high risk for falls. This list is located in a commonly used, HIPAA compliant file location, which was already part of the normal scheduling workflow. These patients are then discussed in the daily huddle to create awareness by all staff and provide “handoff” between visits which by design cannot happen nurse to nurse with each visit. The team has been reviewing the list monthly to develop a sustainability plan. Results: Since the completion of the interactive QI conferences in PDSA cycle 1, there have zero additional falls in the oncology outpatient clinic areas. Continuing on into PDSA cycle 2 with the new handoff process, there have not been any additional falls. Conclusions: This project demonstrates an effective QI intervention to reduce falls in the outpatient oncology areas and prevent injuries in this vulnerable population. This multidisciplinary approach to identifying root causes for falls and reviewing our processes for monitoring patients in our infusion areas ultimately has led to significant reduction in falls. It has also empowered key stakeholders in our oncology clinics with QI tools to address other areas for improvement.


2021 ◽  
pp. 004947552110352
Author(s):  
Ankur Jain ◽  
Nishtha Yadav ◽  
Ashutosh Silodia ◽  
Namrata Khandelwal ◽  
Sanjay Kumar Yadav

Primary hyperparathyroidism is not so uncommon a disease. In high-income countries, with the introduction of routine biochemical testing in 1980s, it is diagnosed early, and the majority are seen as asymptomatic disease. However, in India, a severe symptomatic form is still seen, and many times patients are undiagnosed, thus continuing to suffer debilitating disease. Here, we report such a patient who was being treated as having bony metastases from an unknown primary source, when in fact he had osteitis fibrosa cystica due to primary hyperparathyroidism and was cured after surgery.


2021 ◽  
Vol 8 ◽  
Author(s):  
Sarah A. Vidal ◽  
Katherine A. Skorupski ◽  
Jennifer L. Willcox ◽  
Carrie A. Palm ◽  
Jenna H. Burton

Zoledronic acid (ZOL) is an intravenous bisphosphonate indicated for the use of hypercalcemia of malignancy and management of bony metastases. Its therapeutic effect lies in the targeting of malignant osteoclasts; however, administration can be associated with renal toxicity. The objective of this retrospective study was to evaluate the frequency and severity of acute kidney injury (AKI) following ZOL administration in a cohort of cancer-bearing dogs. A pharmacy search was conducted to identify dogs that received a dose of ZOL between June 2016 and July 2019. Inclusion criteria included baseline and post-treatment chemistry panels. Medical records were reviewed to obtain clinical data including signalment, dose, dosage, number of treatments administered, and changes in renal function. Forty-four dogs met the inclusion criteria. Median number of doses administered was three [interquartile range (IQR), 2–5]. The median highest creatinine value occurred after a median of one dose (IQR, 1–2 doses) compared with the median highest value of blood urea nitrogen, phosphorus, and potassium, which occurred after a median of two doses (IQR, 1–3). Six (13.6%) dogs developed an AKI, and one dog (2.3%) had progression of an existing azotemia after treatment with ZOL was initiated. Two dogs (4.5%) had ZOL treatment discontinued secondary to development of azotemia. Use of concurrent administration of non-steroidal anti-inflammatory drugs or anesthesia did not significantly increase the risk of AKI in this cohort of dogs. Acute kidney injury is observed infrequently in cancer-bearing dogs treated with ZOL and is generally mild to moderate in severity; discontinuation of ZOL due to AKI is uncommon.


2021 ◽  
Vol 15 (1) ◽  
pp. 1-4
Author(s):  
Muhammad Inuwa Mustapha ◽  
◽  
Mustapha Ibrahim Usman ◽  

Colorectal cancer is one of the most common malignancies in the world. Bone metastasis is rare, and data are lacking. Here we report a case of colorectal carcinoma with bony metastasis.


2021 ◽  
Vol 15 (1) ◽  
pp. 78-81
Author(s):  
Muhammad Inuwa Mustapha ◽  
◽  
Mustapha Ibrahim Usman ◽  

Colorectal cancer is one of the most common malignancies in the world. Bone metastasis is rare, and data are lacking. Here we report a case of colorectal carcinoma with bony metastasis.


2021 ◽  
Vol 108 (Supplement_2) ◽  
Author(s):  
D Karunaratne

Abstract A 45-year-old gentleman presented to hospital with vomiting. Bloods demonstrated a corrected calcium of 4.48 and PTH of 979. CT neck showed a right sided thyroid lesion, which on FNA was reported as a possible thyroid or parathyroid neoplasm. A NM scan showed an enhancing nodule in the right thyroid gland and lytic vertebral and pelvic lesions. Bone biopsy showed parathyroid carcinoma. He underwent palliative total thyroidectomy and right superior and inferior parathyroidectomy under the ENT team. His thyroidectomy specimen was reported as right inferior parathyroid carcinoma, infiltrating into the thyroid gland. His calcium levels did not normalise post-surgery and corrected levels were consistently above 3, with PTH > 5000 despite fluid and calcimimetic therapy with only temporary normalisation with bisphosphonates and denosumab. This refractory hypercalcaemia is due to the bony metastases producing PTH, which represents a primary cause of mortality. He is currently being managed with regular fluid infusions and bisphosphonates, with view to commence palliative chemotherapy. Parathyroid carcinoma is extremely rare, and rarer still to present with metastatic disease. Treatment options are limited, with poor evidence behind chemoradiation and immunotherapy. Clinicians should be aware of the complications and management of refractory hypercalcaemia linked to this disease entity.


BMJ ◽  
2021 ◽  
pp. n98
Author(s):  
Samantha Downie ◽  
Elizabeth Bryden ◽  
Fergus Perks ◽  
A Hamish RW Simpson
Keyword(s):  

2021 ◽  
pp. 182-188
Author(s):  
Andrew J. Roth ◽  
Alejandro Gonzalez-Restrepo

This chapter on prostate and genitourinary (GU) cancers focuses on advances in the science of treating prostate, bladder, testicular, kidney, and penile cancers. These cancers are common and are becoming more successfully treated yet can cause significant worry about both longevity and quality of life. Psycho-oncologists can help patients manage the challenges of potential sexual and intimacy issues as well as disruption to one’s body image, distress about treatment decisions, living with active surveillance and with the potential of cancer recurrence, pain and fatigue related to cancer treatments or bony metastases, and end-of-life issues. Men with prostate cancer deal with erectile and urinary dysfunction and attempt to avoid it at all costs in primary treatment decisions. Men with testicular cancer face a life-threatening situation that can interfere with early relationships, career, and body image. People with bladder cancer face the possibility of needing an external apparatus to deal with a heretofore natural bodily function. Even with improved treatments for kidney cancer, patients still cope with significant mortality prediction. Those men with penile cancers deal with very direct invasion of the body image and sexuality. Psycho-oncologists must keep abreast of breakthroughs in new diagnostic tests, which may facilitate more options for active surveillance, as well as new cancer treatments that patients must consider, and the side effects they might encounter. Advocates for improved symptom control including pain management and fatigue improvement are especially important with prostate and GU cancers because patients and families can feel unwarranted shame and embarrassment because of the location of the cancer.


Sign in / Sign up

Export Citation Format

Share Document